Skip to content
10-Q

Quarterly Report

Amphastar Pharmaceuticals, Inc. AMPH

0001297184-26-000033

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 44.09M sh
Shares Diluted Q1 2026 · Mar 31, 2026 46.46M sh
Shares Diluted Q1 2026 · Mar 31, 2025 49.89M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $29.49M
Stock Repurchased Q1 2026 · Mar 31, 2025 $11M
Capex Q1 2026 · Mar 31, 2026 $9.51M
Capex Q1 2026 · Mar 31, 2025 $10.7M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $47.84M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $35.08M
Short Term Investments Q1 2026 · Mar 31, 2026 $121.01M
Short Term Investments Q1 2026 · Dec 31, 2025 $112.64M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $170.94M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $170.18M
Current Liabilities Q1 2026 · Mar 31, 2026 $164.48M
Current Liabilities Q1 2026 · Dec 31, 2025 $158.16M
Total Liabilities Q1 2026 · Mar 31, 2026 $874.77M
Total Liabilities Q1 2026 · Dec 31, 2025 $840.49M
Current Assets Q1 2026 · Mar 31, 2026 $633.68M
Current Assets Q1 2026 · Dec 31, 2025 $636.02M
Total Assets Q1 2026 · Mar 31, 2026 $1.65B
Total Assets Q1 2026 · Dec 31, 2025 $1.63B
Eps Diluted Q1 2026 · Mar 31, 2026 $0.14
Eps Diluted Q1 2026 · Mar 31, 2025 $0.51
Eps Basic Q1 2026 · Mar 31, 2026 $0.14
Eps Basic Q1 2026 · Mar 31, 2025 $0.53
Sga Expense Q1 2026 · Mar 31, 2026 $18.03M
Sga Expense Q1 2026 · Mar 31, 2025 $16M
Rd Expense Q1 2026 · Mar 31, 2026 $26.74M
Rd Expense Q1 2026 · Mar 31, 2025 $20.1M
Net Income Q1 2026 · Mar 31, 2026 $6.42M
Net Income Q1 2026 · Mar 31, 2025 $25.29M
Operating Income Q1 2026 · Mar 31, 2026 $13.63M
Operating Income Q1 2026 · Mar 31, 2025 $37.29M
Gross Profit Q1 2026 · Mar 31, 2026 $70.32M
Gross Profit Q1 2026 · Mar 31, 2025 $85.25M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $100.85M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $85.28M
Revenue Q1 2026 · Mar 31, 2026 $171.17M
Revenue Q1 2026 · Mar 31, 2025 $170.53M